Isofol appoints Roger Tell as Chief Medical Officer ahead of initiation of clinical study
GOTHENBURG, Sweden, February 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that Roger Tell has been […]
News
Isofol announces the presentation of a post-hoc analysis of the phase III study AGENT at the 2025 ASCO GI symposium
GOTHENBURG, Sweden, January 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that an abstract of the
Isofol and its partner Solasia plan to expand the upcoming clinical trial of arfolitixorin to Japan
GOTHENBURG, Sweden, December 18, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that its partner Solasia Pharma
Isofol announces that an investigator-initiated study of arfolitixorin has been published in BJC Reports
GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the investigator-initiated Modelle study,
Isofol provides an operational update during investor meeting
GOTHENBURG, Sweden, November 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), will provide an operational update during today’s
Isofol appoints nomination committee ahead of the Annual General Meeting 2025
GOTHENBURG, Sweden, November 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Isofol Medical AB (publ) publishes interim report, January–September 2024
GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
Isofol announces that an abstract has been accepted for presentation at ASCO GI 2025
GOTHENBURG, SWEDEN, November 11, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that an abstract with results
Isofol invites to investor meeting on November 20, 2024
GOTHENBURG, Sweden, October 25, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an
A Late Breaking Abstract concerning arfolitixorin will be presented at ENA 2024 today
GOTHENBURG, SWEDEN, October 23, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract